Anap­tys­Bio takes a beat­ing as its lead drug fails its first PhII test. And 5 more tri­als are near­ing a read­out

Anap­tys­Bio shares got ham­mered Mon­day morn­ing af­ter the biotech con­ced­ed de­feat for the first mid-stage test of its lead drug.

Its an­ti­body im­si­dolimab per­formed around …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER